Abstract
Lung transplantation may offer longer survival and improved quality of life to patients with end-stage lung disease. Common indications for single lung transplantation include chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and interstitial lung disease other than idiopathic pulmonary fibrosis. Bilateral lung transplantation is the norm for cystic fibrosis, but the proportion of bilateral (double) lung transplantation procedures has been rising for other major indications as well. The median overall survival for patients after lung transplantation is currently 6.7 years with a moderate survival advantage for patients with bilateral lung transplantation. Complications of lung transplantation may be related to (1) the operation itself (primary graft dysfunction, anastomotic complications), (2) the host’s immunologic response to the allograft (rejection), and (3) the immunosuppressive therapy used to prevent rejection (infection, posttransplantation lymphoproliferative disorder [PTLD]). Other complications, such as recurrence of the original disease or aspiration, may also occur. Posttransplantation transbronchial biopsy may be performed for a specific clinical indication or for surveillance of acute rejection. The histopathologic findings most commonly encountered in a posttransplantation transbronchial biopsy include acute rejection, infection, airway-centered inflammation, obliterative bronchiolitis, harvest injury, and PTLD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.